Antibe Therapeutics is a publicly traded biotechnology company pursuing a breakthrough advance in the treatment of inflammation. Their drug pipeline addresses major markets in non-addictive management of chronic and post-surgical pain. Antibe’s lead drug, now in late Phase 2 trials, is demonstrating unprecedented safety in the treatment of chronic pain, a condition that affects more than…More 50 million Americans alone. Their second pipeline drug is intended to replace a range of opioids, addressing a vast and pressing public health concern. Their third drug is a safer daily aspirin -- delivering anti-stroke and anti-cancer benefits without damage to the digestive tract.